IP
EDIT icon

Intellectus Partners’s Editas Medicine EDIT Stock Holding History

Intellectus Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-500
Closed -$8K – 695
2016
Q4 		$8K Buy
+500
New +$7.59K ﹤0.01% 542

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Intellectus Partners's EDIT Position: Q1 2017 in Review

Intellectus Partners sold out of Editas Medicine (EDIT) in Q1 2017, closing a stake of 500 shares — an estimated $8K sold.

Intellectus Partners first reported a position in EDIT in Q4 2016 and held it in 1 quarter. The position peaked at $8K in Q4 2016. 99 funds tracked by Wall St. Rank hold EDIT as of Q1 2017.

  • Intellectus Partners reported no remaining Editas Medicine position as of Q1 2017 after selling out during the quarter.
  • Intellectus Partners sold 500 Editas Medicine shares in Q1 2017, an estimated $8K.
  • Intellectus Partners first reported a position in Editas Medicine in Q4 2016 and held it in 1 quarter.
  • Intellectus Partners's Editas Medicine position peaked at $8K in Q4 2016.
  • 99 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2017.

Based on Intellectus Partners's 13F filing for Q1 2017, filed 8 May 2017.